Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer

NCT ID: NCT05954078

Last Updated: 2024-05-20

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 340 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-01
• Study Completion Date: 2028-06-30

Brief Summary

Colorectal cancer (CRC) is one of the most common gastrointestinal tumors. According to the latest cancer report, the incidence and mortality rates of CRC are both ranked top 5 among malignant tumors worldwide and continue to rise. Patients who receive treatment in the early stage (stage I) have a 5-year survival rate of approximately 90%. However, for high-risk stage II and III colorectal cancer patients, the 5-year survival rate is only 40%-70%, and almost half of the patients experience postoperative recurrence and metastasis.

Evidence suggests that Stage III CRC patients can benefit from standard adjuvant chemotherapy. It is worth noting that some high-risk stage II patients, especially those with T4N0, have a poorer prognosis compared to stage IIIA (T1-2N+). Adjuvant chemotherapy is now also recommended for postoperative cases of high-risk stage II CRC. Given the high effectiveness of the three-drug FOLFOXIRI regimen in treating metastatic CRC and the success of adjuvant chemotherapy in treating pancreatic cancer, the combination of 5-fluorouracil, oxaliplatin, and irinotecan may have a synergistic effect.

Extensive study results have shown that: (a) The status of ctDNA methylation after surgery is significantly correlated with patient prognosis, and patients who are positive for ctDNA methylation in the first 1-4 weeks after surgery (before adjuvant chemotherapy) have a poor prognosis. (b) Patients who are ctDNA methylation positive in the first 1-4 weeks after surgery (before adjuvant chemotherapy) can benefit from adjuvant chemotherapy, and achieving ctDNA methylation negativity through adjuvant chemotherapy significantly improves patient prognosis. This project focuses on exploring the optimized mode of postoperative adjuvant chemotherapy for high-risk stage II and III CRC guided by ctDNA methylation, which has high scientific and innovative value.

This multicenter, prospective, and randomized controlled cohort study uses a single-tube methylation-specific quantitative PCR (mqMSP) detection, which detects 10 different methylation markers and can quantitatively analyze plasma samples containing tumor DNA as low as 0.05%. This study will use this ctDNA methylation detection technology to perform quantitative detection of ctDNA methylation in the plasma of enrolled patients, and explore the effect of different chemotherapy regimens on ctDNA clearance rate and the prognostic value for ctDNA positive patients. We hope to screen out high-risk populations for recurrence through postoperative ctDNA testing, and administer more intensive chemotherapy regimens (chemotherapy upgrading) as early as possible to improve ctDNA clearance rate and patient prognosis.

Conditions

High-risk Stage II Colorectal Cancer; Stage III Colorectal Cancer; Circulating Tumor DNA Methylation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

mFOLFIRINOX adjuvant chemotherapy

Patients will receive mFOLFIRINOX once every two weeks for 6 cycles as adjuvant chemotherapy, after which a blood test is conducted to check the status of ctDNA. If the ctDNA remains positive, the treatment continues for another 6 cycles. If the ctDNA becomes negative, then maintenance chemotherapy with single-agent capecitabine is given once every 21 days for 4 cycles.

Group Type: EXPERIMENTAL

mFOLFIRINOX adjuvant chemotherapy

Intervention Type: DRUG

mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles

mFOLFOX6/XELOX adjuvant chemotherapy

Patients will receive mFOLFOX6 once every two weeks for 6 cycles or XELOX once every three weeks for 4 cycles as adjuvant chemotherapy. After the treatment, a blood test is conducted to check the status of ctDNA. If the ctDNA remains positive, the treatment continues with another 6 cycles of mFOLFOX 6 or 4 cycles of XELOX given once every 21 days. If the ctDNA becomes negative, then maintenance chemotherapy with single-agent capecitabine is given once every 21 days for 4 cycles.

Group Type: ACTIVE_COMPARATOR

mFOLFOX6/XELOX adjuvant chemotherapy

Intervention Type: DRUG

mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles or XELOX (oxaliplatin 130mg/m2, ivgtt, Q3w; capecitabine 1000mg/m2, p.o, Q3w) for 8 cycles

Interventions

mFOLFIRINOX adjuvant chemotherapy

mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles

Intervention Type: DRUG

mFOLFOX6/XELOX adjuvant chemotherapy

mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles or XELOX (oxaliplatin 130mg/m2, ivgtt, Q3w; capecitabine 1000mg/m2, p.o, Q3w) for 8 cycles

Intervention Type: DRUG

Other Intervention Names

Oxaliplatin; Irinotecan; Leucovorin; 5-Fluorouracil; Oxaliplatin; Leucovorin; 5-Fluorouracil

Eligibility Criteria

Inclusion Criteria

Patients who have been histopathologically diagnosed with colorectal adenocarcinoma;

Patients who have undergone radical curative resection of the primary tumors;

Patients with CRC of high-risk stage II and stage III based on final findings (UICC TNM Classification, 8th Edition);

Patients who tested positive for ctDNA methylation at 5-7 days after surgery prior to enrollment;

Patients with no obvious relapse confirmed by chest, abdominal, and pelvic CT scans, etc.;

Patients aged ≥ 18 and ≤80 years old, regardless of gender;

Patients with expected survival of more than 12 months;

Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;

Patients who have no severe disorder in major organs (such as the bone marrow, heart, lungs, liver, and kidneys) and meet the following criteria: Neutrophil count ≥ 1,500/mm3, Platelet count ≥ 100,000/mm3, Hemoglobin ≥ 8.0 g/dL, Serum creatinine ≤ 1.5 mg/dL, Total bilirubin ≤ 1.5 mg/dL, ALT and AST ≤ 100 U/L

Patients with no diarrhea or stomatitis of Grade 2 or severer according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0;

Patients who voluntarily gave written consent to participate in the trial after receiving a thorough explanation of the trial before enrolling in the trial

Exclusion Criteria

Neoadjuvant therapy performed before operation;

Blood transfusion performed during operation or within 2 weeks before operation;

Incomplete baseline samples, including preoperative plasma samples and plasma samples 5-7 days after operation;

Pregnant or lactating women who have fertility and do not take adequate contraceptive measures;

Have a history of other malignant tumors within 5 years, except cured cervical carcinoma in situ or non melanoma skin cancer;

Primary brain tumor or central nerve metastasis is not under control, with obvious intracranial hypertension or neuropsychiatric symptoms;

Patients with the following serious or uncontrollable diseases: severe heart disease, the condition is still unstable after treatment, including myocardial infarction, congestive heart failure, unstable angina pectoris, pericardial effusion with obvious symptoms or unstable arrhythmia within 6 months before enrollment; definite neuropathy or psychosis, including dementia or seizures; severe or uncontrolled infection; active disseminated intravascular coagulation and obvious bleeding tendency;

Significant impairment of important organ function;

Other conditions in which the investigator believes that the patient should not participate in this trial

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fudan University

OTHER

Sponsor Role: lead

Responsible Party

Junjie Peng

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Facility Contacts

Junjie Peng, MD, PhD

Role: primary

pengjj67@hotmail.com

86-18017317122

Shaobo Mo, MD, PhD

Role: backup

shaobom@126.com

86-18121290562

Other Identifiers

FINE Trial

Identifier Type: -

Identifier Source: org_study_id